We are not able to offer medical, pharmaceutical or nutritional advice. Please consult a healthcare professional.

Brand Name Generic name IBS type Type Comments
Bekinda® ondansetron IBS-D A patent-protected, extended-release (24 hours) oral pill formulation of ondansetron. Ondansetron is a 5-HT3 antagonist.
Blautix All IBS types Single-strain bacteria that consumes gases which are known to cause bloating, abdominal pain and changes in bowel frequency.
Ibodutant® tachykinin NK2 IBS-D Tachykinin NK2 receptor antagonist. Proposed as a potential novel drug for the therapy of gastrointestinal diseases characterized by motility alterations, visceral pain, and/or inflammation, such as IBS.
IBset® / Nasea® / Nozia® / Irribow® ramosetron IBS-D Improves abnormal bowel movement associated with the acceleration of intestinal transit by inhibiting 5-HT3 receptor selectively. It also improves visceral hypersensitivity by suppressing the transmission of intestinal nociception.
ORP-101® buprenorphine IBS-D A buprenorphine dimer therapeutic, is a peripherally active partial mu opioid receptor agonist and K opioid receptor antagonist designed to ease colonic hypersensitivity stemming from intestinal hyperalgesia and motility dysfunction in IBS-D.
SYN-010® lovastatin lactone IBS-C A proprietary, modified-release formulation of lovastatin lactone that is designed to reduce methane production in the intestine, curbing IBS-C.
Tenapanor® NHE3 IBS-C Non-systemic small molecule inhibitor of NHE3, a sodium transporter present on the epithelia surface of the GI tract. Reduces the absorption of dietary sodium and phosphorus thereby relieving IBS-C.
Vibegron® IBS-A Studied in women with abdominal pain due to IBS with predominant diarrhea (IBS-D) or mixed episodes of diarrhea and constipation (IBS-M). Vibegron is an investigational oral beta-3 adrenergic receptor agonist currently being assessed for the treatment of overactive bladder.